FDG PET/CT在自体干细胞移植评估中的应用
本文综述了FDG-PET/CT在自体干细胞移植(autoSCT)评估中的作用,重点讨论淋巴瘤和多发性骨髓瘤。对于复发/难治性霍奇金淋巴瘤,移植前FDG-PET/CT阴性是移植后结局的重要预后因素;非霍奇金淋巴瘤的数据更多变。多发性骨髓瘤中FDG-PET/CT已成为评估治疗反应的推荐影像方法,可能提供移植后结局的预后和预测价值。
要点
- 复发/难治性霍奇金淋巴瘤移植前FDG-PET/CT阴性是移植后结局的重要预后因素。
- 非霍奇金淋巴瘤移植前FDG-PET/CT的预后数据更多变。
- 多发性骨髓瘤中FDG-PET/CT是评估治疗反应的推荐影像方法。
核心结论
- FDG-PET/CT在自体干细胞移植评估中具有预后价值,尤其在淋巴瘤和多发性骨髓瘤中。
研究设计与样本
- 本文为综述,讨论FDG-PET/CT在自体干细胞移植评估中的研究进展。
主要发现
- 复发/难治性霍奇金淋巴瘤移植前FDG-PET/CT阴性是移植后结局的重要预后因素,与既往方案数量无关。
- 非霍奇金淋巴瘤移植前FDG-PET/CT数据更多变。
- 霍奇金和非霍奇金淋巴瘤研究主要采用视觉评估,Deauville评分为当前标准标准。
- 多发性骨髓瘤中FDG-PET/CT已成为评估治疗反应的推荐影像方法。
- 数据提示FDG-PET/CT可能为自体干细胞移植后结局提供预后和预测价值。
关键数值与推荐
- 霍奇金和非霍奇金淋巴瘤的FDG-PET/CT解读主要采用视觉评估,Deauville评分为当前标准标准。
临床怎么用
- 在自体干细胞移植前对霍奇金淋巴瘤患者行FDG-PET/CT评估,阴性结果支持较好移植后结局。
- 多发性骨髓瘤治疗反应评估可优先采用FDG-PET/CT。
局限性
- 非霍奇金淋巴瘤移植前FDG-PET/CT数据更多变。
- 特定方案移植前阈值优化及附加半定量参数整合仍是活跃研究领域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The appropriate selection of patients to undergo hematopoietic stem cell transplant (HSCT) is critical due to the risk of treatment-related morbidity and mortality. The prognostic value of FDG-PET/CT in response assessment in hematologic malignancies is well-established and has led to numerous investigations into the role of FDG-PET/CT in the evaluation of patients in the setting of HSCT. This article discusses the most common indications for autologous stem cell transplant (autoSCT) in which FDG-PET/CT has been evaluated, including for lymphoma and multiple myeloma. For relapsed/refractory Hodgkin lymphoma, achieving a negative FDG-PET/CT scan, regardless of the number of the regimens, prior to autoSCT is an important prognostic factor for posttransplant outcome. The data in the pretransplant setting are more variable for non-Hodgkin lymphoma. For both Hodgkin and non-Hodgkin lymphoma, studies have primarily used a visual assessment for FDG-PET/CT interpretation, with the Deauville score the current standard criteria. Optimization of thresholds for specific regimens pretransplant as well as integration of additional semiquantitative parameters to assess response remain active areas of research. For multiple myeloma, FDG-PET/CT has emerged as the recommended imaging modality of choice for assessing response to treatment. Data suggest that FDG-PET/CT may provide prognostic and predictive value for assessing outcome after autoSCT.
引用
- Jacene HA. FDG PET for Assessment of Autologous Stem Cell Transplantation. Semin Nucl Med. 2021. PMID: 33531164. doi:10.1053/j.semnuclmed.2021.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。